BioSpace News Archive

Growing cases of post herpetic neuralgia treatment are increasing the number of referrals to pain management clinics resulting in growth of market. According to a latest research by Persistence Market Research (PMR), the global post herpetic neuralgia treatment market is anticipated to account for over US$ 908.4 Mn, in terms of value, by 2026 end.

Increasing prevalence of pressure ulcer and increasing adoption coupled with increasing acquaintance of heel pressure injury relieving devices expected to gain traction throughout the forecast period in the heel pressure injury relieving devices market.

According to the latest market report published by the company titled ‘Sarcopenia Treatment Market: Global Industry Analysis 2013 – 2017 and Forecast, 2018 – 2026,’ the global sarcopenia treatment market is projected to reach US$ 3,302.0 Mn by the end of 2026 and grow at a CAGR of 4.2% during the forecast period.

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer.

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, applauds Biogen’s initiation of BLA (biologics license application) submission to the U.S. Food and Drug Administration (FDA) for aducanumab, its Alzheimer’s disease candidate targeting amyloid beta

Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that it has entered into a Letter of Intent with the pan-Canadian Pharmaceutical Alliance regarding RADICAVA®, an intravenous infusion treatment for amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.

Real-time RT-PCR-based test enables fast, on demand and fully automated detection of early COVID-19 infections for rapid isolation and treatment guidance;

Lysogene, a pioneering Phase 3 gene therapy platform company targeting central nervous system diseases, announced its 2019 financial results, approved by the Board of Directors on 21 April 2020.

BioArctic has not experienced any noteworthy disruptions to its operations owing to the COVID-19 pandemic.

Diamond Pharma Services announced its pharmacovigilance division, Diamond PV Services, has acquired PharmaCentral, an innovative pharmacovigilance services and medical affairs business based in Dublin, Ireland.